Current Management of Neonatal Neuroblastoma
Rodrigo B. Interiano,
Andrew M. Davidoff.
Neonatal neuroblastoma accounts for less than 5% of all cases of neuroblastoma but carries
a favorable prognosis with most patients being stratified into low- or intermediate-risk groups for recurrence
of disease. The epidemiology of neonatal (age less than 30 days) neuroblastoma contrasts
greatly with patients older than 30 days. Owing to the unique potential for spontaneous regression of
this tumor type, several groups have sought to reduce therapy given to neonates with neuroblastoma
and use a watch-and-wait approach for many low-risk patients. Ongoing studies also seek to reduce
therapy for some intermediate-risk patients in an attempt to lessen exposure to surgical intervention
and cytotoxic chemotherapy. In this review, we discuss the epidemiology, clinical presentation, staging, and treatment for
neonates with neuroblastoma.
Keywords: Neuroblastoma, neonatal, regression.
Rights & PermissionsPrintExport